Saturday 17 October 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 55.9% and free cash flow fell 30.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
37.19
1.01
−2.64%
Follow EWTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(30.02%) | (34.19%) | (38.14%) | (38.03%) | |
| (28.73%) | (32.29%) | (36.18%) | (36.09%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(28.06%) | (32.03%) | (35.58%) | (43.89%) | |
Free Cash Flow per Share |
(1.26) | (1.40) | (1.39) | (1.48) | |
Free Cash Flow |
(132.64) | (144.07) | (148.96) | (158.83) | |
Capital Expenditures |
(0.46) | (0.26) | (0.47) | (0.45) | |
| Other line items | |||||
Cash ROIC |
(11.82%) | (13.69%) | (15.01%) | (17.48%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.84 | 0.86 | 0.84 | 0.80 | |
Depreciation/Fixed assets |
(0.80) | (0.69) | (0.60) | (0.44) | |
Capex/Depreciation |
0.07 | 0.05 | 0.11 | 0.15 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.25) | (1.40) | (1.39) | (1.47) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates